Hematologists are continually striving to follow established practice norms and provide the best treatment possible for patients with blood illnesses. Treatment, on the other hand, was never a precise science. Opinions disagree on the optimum strategy; sometimes more than one treatment technique produces equal results, or therapies differ only in how they fail. Furthermore, a hematologist is constrained by economic limits in the local area. Patients are not all the same over the world. Early presentation is more typical in the developed world, as is the patient’s comprehension of the illness process. This, in turn, affects how patients are managed, how strictly they adhere to the treatment regimen and the outcome. For a study, researchers examined the precursor B-cell acute lymphoblastic leukemia in a teenager in a variety of settings ranging from low- to high-income nations, with considerably varying barriers for diagnosis, therapy, and follow-up. 

For these reasons, even though the beginning circumstances were the same, patients were treated differently depending on the institute and the nation they were in. Experts from all around the world have been charged with describing their treatment strategy and reasoning for a given illness presentation. They looked at the treatment of precursor B-cell acute lymphoblastic leukemia (pre-B ALL) at five different institutions throughout the world, with an emphasis on those with more or less tight budgets. They concluded with a conclusion from a subject matter expert comparing and contrasting the various management styles, as well as weighing their benefits and drawbacks.